We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFRM icon
326
Affirm
AFRM
$25.5B
– –
-2,339
Closed -$174K
AGNC icon
327
CALL
AGNC Investment
AGNC
$12.9B
– –
-936
Closed -$3.74K
ALHC icon
328
Alignment Healthcare
ALHC
$4.26B
– –
-83,543
Closed -$1.65M
ALNY icon
329
Alnylam Pharmaceuticals
ALNY
$35.7B
– –
-1,433
Closed -$570K
ALT icon
330
CALL
Altimmune
ALT
$558M
– –
-1,324
Closed -$13
AMLX icon
331
Amylyx Pharmaceuticals
AMLX
$1.97B
– –
-31,147
Closed -$376K
AMZN icon
332
Amazon
AMZN
$2.66T
– –
-1,600
Closed -$369K
ANIP icon
333
ANI Pharmaceuticals
ANIP
$1.8B
– –
-14,320
Closed -$1.13M
APGE icon
334
Apogee Therapeutics
APGE
$10.1B
– –
-2,445
Closed -$178K
APLT
335
CALL
DELISTED
Applied Therapeutics
APLT
– –
-55
Closed -$1
AQST icon
336
CALL
Aquestive Therapeutics
AQST
$517M
– –
-566
Closed -$65K
AQST icon
337
PUT
Aquestive Therapeutics
AQST
$517M
– –
-906
Closed -$59.4K
ARDX icon
338
Ardelyx
ARDX
$1.28B
– –
-60,490
Closed -$353K
ASND icon
339
Ascendis Pharma A/S
ASND
$17.1B
– –
-1,832
Closed -$411K
ATAI icon
340
AtaiBeckley Inc
ATAI
$2.66B
– –
-43,973
Closed -$180K
AVGO icon
341
Broadcom
AVGO
$1.76T
– –
-360
Closed -$125K
JBIO
342
Jade Biosciences
JBIO
$1.27B
– –
-12,469
Closed -$181K
AXON
343
Axon Enterprise
AXON
$41.1B
– –
-1,000
Closed -$568K
BAC icon
344
Bank of America
BAC
$430B
– –
-21,050
Closed -$1.16M
BBIO icon
345
CALL
BridgeBio Pharma
BBIO
$15.9B
– –
-376
Closed -$868K
BBIO icon
346
PUT
BridgeBio Pharma
BBIO
$15.9B
– –
-536
Closed -$72K
BCRX icon
347
BioCryst Pharmaceuticals
BCRX
$2.36B
– –
-51,701
Closed -$403K
BCS icon
348
Barclays
BCS
$93.8B
– –
-23,000
Closed -$585K
BDTX icon
349
CALL
Black Diamond Therapeutics
BDTX
$103M
– –
-512
Closed -$13.1K
BILI icon
350
Bilibili
BILI
$7.55B
– –
-30,000
Closed -$738K
12 13
14
15 16

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.